NCT05724329View on ClinicalTrials.gov

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 5, 2023

Primary Completion Date

April 5, 2024

Study Completion Date

August 5, 2028

Conditions
Head and Neck Squamous Cell Carcinomas
Interventions
DRUG

Tislelizumab + Dasatinib + Quercetin (neoadjuvant)

Patients receive Tislelizumab (IV) on day 1, dasatinib (PO) on day 1,2,3 and quercetin (PO) on day 1,2,3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

PROCEDURE

surgery

Standard of care

DRUG

Tislelizumab + Dasatinib + Quercetin (adjuvant)

Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10

Trial Locations (1)

510000

Sun Yat-sen Memorial Hospital, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER